Pitcairn Co. Trims Stock Holdings in Johnson & Johnson $JNJ

Key Points

• Pitcairn Co. trimmed its Johnson & Johnson stake by 23.7% in Q3, selling 11,803 shares and leaving it with 38,087 shares worth $7.06 million, about 0.6% of Pitcairn's portfolio (its 26th-largest holding).
• Company insiders sold a total of 30,142 J&J shares in the past 90 days — including EVP Timothy Schmid (22,623 shares) and EVP Vanessa Broadhurst (6,197 shares) — leaving insiders with just 0.16% ownership.
• FDA approval of TECVAYLI plus DARZALEX for relapsed/refractory multiple myeloma could meaningfully expand J&J’s oncology revenue potential, and the firm also declared a $1.30 quarterly dividend (2.2% yield, ex-dividend Feb 24).

Pitcairn Co. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 23.7% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 38,087 shares of the company's stock after selling 11,803 shares during the period. Johnson & Johnson accounts for 0.6% of Pitcairn Co.'s portfolio, making the stock its 26th biggest holding. Pitcairn Co.'s holdings in Johnson & Johnson were worth $7,062,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smith Moore & CO. raised its stake in Johnson & Johnson by 1.0% during the 3rd quarter. Smith Moore & CO. now owns 24,081 shares of the company's stock worth $4,465,000 after acquiring an additional 250 shares during the period. Islay Capital Management LLC raised its position in shares of Johnson & Johnson by 12.4% during the 3rd quarter. Islay Capital Management LLC now owns 9,663 shares of the company's stock valued at $1,792,000 after purchasing an additional 1,065 shares during the period. Crossmark Global Holdings Inc. lifted its stake in shares of Johnson & Johnson by 0.3% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 41,914 shares of the company's stock valued at $7,772,000 after buying an additional 126 shares in the last quarter. Orcam Financial Group boosted its holdings in Johnson & Johnson by 25.9% in the 3rd quarter. Orcam Financial Group now owns 1,700 shares of the company's stock worth $315,000 after buying an additional 350 shares during the period. Finally, Winch Advisory Services LLC increased its stake in Johnson & Johnson by 4.3% in the 3rd quarter. Winch Advisory Services LLC now owns 3,516 shares of the company's stock worth $652,000 after buying an additional 145 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other news, EVP Timothy Schmid sold 22,623 shares of the firm's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $244.33, for a total value of $5,527,477.59. Following the completion of the sale, the executive vice president directly owned 26,769 shares of the company's stock, valued at $6,540,469.77. This trade represents a 45.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business's stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the transaction, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the topic of several research analyst reports. Guggenheim boosted their price objective on Johnson & Johnson from $227.00 to $240.00 and gave the company a "buy" rating in a research report on Friday, January 23rd. JPMorgan Chase & Co. boosted their price target on Johnson & Johnson from $225.00 to $250.00 and gave the stock a "neutral" rating in a report on Thursday. Royal Bank Of Canada upped their price target on Johnson & Johnson from $240.00 to $255.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 3rd. Citigroup lifted their price objective on shares of Johnson & Johnson from $232.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, January 22nd. Finally, Argus boosted their target price on shares of Johnson & Johnson from $210.00 to $240.00 in a report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $234.87.

Johnson & Johnson Stock Down 2.3%

Shares of JNJ opened at $239.65 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a market capitalization of $577.53 billion, a price-to-earnings ratio of 21.69, a price-to-earnings-growth ratio of 2.42 and a beta of 0.34. Johnson & Johnson has a 1 year low of $141.50 and a 1 year high of $251.71. The business's 50 day simple moving average is $227.70 and its 200-day simple moving average is $203.56.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The company had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. As a group, equities analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson's dividend payout ratio is currently 47.06%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA approval for TECVAYLI® (teclistamab) in combination with DARZALEX FASPRO® for relapsed/refractory multiple myeloma expands J&J’s label into earlier lines of therapy, with Phase 3 data showing significant progression‑free and overall survival benefits — a potential new standard of care and meaningful long‑term revenue upside for the oncology portfolio. PR Newswire: TECVAYLI + DARZALEX approval Reuters: FDA approves JNJ blood cancer drug
• Neutral Sentiment: JPMorgan raised its price target to $250 but kept a "neutral" rating — the higher target signals upside potential acknowledged by analysts, yet the maintained rating tempers immediate buy-side enthusiasm. Benzinga / TickerReport: JPMorgan price target
• Neutral Sentiment: J&J launched a direct‑to‑consumer website to sell certain drugs to uninsured or out‑of‑pocket U.S. patients — a strategic move to improve access and potentially capture incremental retail revenue, though initial impact on top line is uncertain. Reuters: direct-to-consumer site
• Neutral Sentiment: Pipeline progress: J&J is advancing nipocalimab (Fast Track for SLE) with Phase 3 underway — positive R&D momentum that supports future growth, offset by competing legal/claim disputes noted in coverage. Yahoo Finance: nipocalimab progress & legal challenge
• Negative Sentiment: Two J&J units agreed to pay $65 million to settle a Tracleer antitrust class action alleging overcharges — a direct legal expense and reminder of ongoing litigation risks, though the amount is modest versus J&J’s market cap. Reuters: $65M Tracleer settlement
• Negative Sentiment: Market reaction: coverage notes J&J shares declined more than the broader market during the session, reflecting that investors are weighing legal/settlement headlines and profit‑taking despite the positive FDA news. Zacks: JNJ declines more than market

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.